AI-generated summary
The authors report a randomized trial in China of adolescent and adult patients with port-wine stain, comparing hemoporfin photodynamic therapy with a 532 nm laser against placebo with laser. At week 8, 89.7% of the hemoporfin group and 24.5% of the placebo group showed at least some improvement, as judged by blinded clinicians. Hyperpigmentation was reported as a common side effect.
- Who or what was studied
- Adolescent and adult patients aged 14 to 65 years with port-wine stain, enrolled at eight hospitals in China
- Wavelengths
- 532 nm
- Limits stated in the abstract
- The abstract does not state a limitation of the study; treatment reactions and hyperpigmentation were common, and the stated safety conclusion rests on these reported adverse events.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background And Objectives
Photodynamic therapy (PDT) has shown potentially beneficial results in treating port-wine stain, but its benefit-risk profile remains undefined. This study aimed to evaluate the efficacy and safety of PDT conducted with hemoporfin and a 532 nm continuous wave laser to treat port-wine stain clinically.
Patients And Methods
This randomized clinical trial was conducted in eight hospitals in China. Participants were adolescent and adult patients (age range: 14-65 years old) with port-wine stain. During stage 1 (day 1 to week 8) all patients were randomized at a 3:1 ratio to treatment (532 nm laser irradiation (96-120 J/cm2) with hemoporfin (5mg/kg; PDT-hemoporfin, n = 330)) or placebo groups (irradiation with placebo (PDT-placebo, n = 110)); during stage 2 (week 8 to 16) patients in both groups were offered treatment. Clinician-evaluators, who were blind to the study, classified each case on the following four-level scale according to assessment of before and after standardized pictures of the lesion area: no improvement: <20%; some improvement: 20-59%; great improvement: 60-89%; or nearly completely resolved: ≥90%. The primary efficacy endpoint was proportion of patients achieving at least some improvement at week 8. The secondary efficacy endpoints were proportion of patients achieving nearly completely resolved or at least great improvement at week 8, proportion of patients achieving early completely resolved, at least great improvement, or at least some improvement at week 16, and the corresponding satisfaction of the investigators and the patients (designated as 'excellent', 'good', 'moderate', or 'ineffective') at weeks 8 and 16.
Results
Compared to the PDT-placebo group, the PDT-hemoporfin group showed a significantly higher proportion of patients that achieved at least some improvement (89.7% [n = 295; 95% CI, 85.9%-92.5%] vs. 24.5% [n = 27; 95% CI, 17.4%-33.3%]) at week 8 (P < 0.0001) and higher improvements for all secondary efficacy endpoints. Treatment reactions occurred in 99.5% (n = 731; 95% CI, 98.7%-99.8%) of the PDT-hemoporfin treatments (n = 735). Hyperpigmentation occurred in 22.9 per 100 patient-treatments (n = 168; 95% CI, 20.0-26.0) in the PDT-hemoporfin treated patients.
Conclusions
Hemoporfin-mediated PDT is an effective and safe treatment option for adolescent and adult patients with port-wine stain.
Trial Registration
Chinese Clinical Trial Registry ChiCTR-TRC-08000213.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 532 nm
- Energy density (fluence)
- 120 J/cm2
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, Randomized controlled trial, Laser, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.